Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies

Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431

Anderson, 2015, The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis, PLoS One, 10, e0140908, 10.1371/journal.pone.0140908

Alisi, 2012, Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach, Nat Rev Gastroenterol Hepatol, 9, 152, 10.1038/nrgastro.2011.273

2017, Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 390, 1211, 10.1016/S0140-6736(17)32154-2

2017, Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 390, 1345, 10.1016/S0140-6736(17)32366-8

Pearson-Stuttard, 2018, Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment, Lancet Diabetes Endocrinol, 6, e6, 10.1016/S2213-8587(18)30150-5

Younossi, 2015, Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009, Hepatology, 62, 1723, 10.1002/hep.28123

Micha, 2017, Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States, JAMA, 317, 912, 10.1001/jama.2017.0947

Khera, 2016, Genetic risk, adherence to a healthy lifestyle, and coronary disease, N Engl J Med, 375, 2349, 10.1056/NEJMoa1605086

Stefan, 2016, Divergent associations of height with cardiometabolic disease and cancer: epidemiology, pathophysiology, and global implications, Lancet Diabetes Endocrinol, 4, 457, 10.1016/S2213-8587(15)00474-X

Eslamparast, 2017, Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease, Nutrients, 9, 800, 10.3390/nu9080800

Ekstedt, 2015, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up, Hepatology, 61, 1547, 10.1002/hep.27368

Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043

Yki-Järvinen, 2014, Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome, Lancet Diabetes Endocrinol, 2, 901, 10.1016/S2213-8587(14)70032-4

Stefan, 2016, Phenotypes of prediabetes and stratification of cardiometabolic risk, Lancet Diabetes Endocrinol, 4, 789, 10.1016/S2213-8587(16)00082-6

Stefan, 2017, Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans, Cell Metab, 26, 292, 10.1016/j.cmet.2017.07.008

Bril, 2017, Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action, Diabetes Care, 40, 419, 10.2337/dc16-1787

Bril, 2017, Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease, Hepatology, 65, 1132, 10.1002/hep.28985

Gastaldelli, 2017, Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?, Clin Sci (Lond), 131, 2701, 10.1042/CS20170987

Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012

Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109

Rinella, 2015, Nonalcoholic fatty liver disease: a systematic review, JAMA, 313, 2263, 10.1001/jama.2015.5370

Stefan, 2018, Metabolically healthy obesity: the low-hanging fruit in obesity treatment?, Lancet Diabetes Endocrinol, 6, 249, 10.1016/S2213-8587(17)30292-9

Donnelly, 2005, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, 1343, 10.1172/JCI23621

Stefan, 2008, Causes and metabolic consequences of fatty liver, Endocr Rev, 29, 939, 10.1210/er.2008-0009

Petersen, 2017, Roles of diacylglycerols and ceramides in hepatic insulin resistance, Trends Pharmacol Sci, 38, 649, 10.1016/j.tips.2017.04.004

Marra, 2018, Lipotoxicity and the gut-liver axis in NASH pathogenesis, J Hepatol, 68, 280, 10.1016/j.jhep.2017.11.014

Bacchi, 2013, Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial), Hepatology, 58, 1287, 10.1002/hep.26393

Lomonaco, 2013, Nonalcoholic fatty liver disease: current issues and novel treatment approaches, Drugs, 73, 1, 10.1007/s40265-012-0004-0

Kennedy, 2014, Geroscience: linking aging to chronic disease, Cell, 159, 709, 10.1016/j.cell.2014.10.039

Kalinkovich, 2017, Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis, Ageing Res Rev, 35, 200, 10.1016/j.arr.2016.09.008

Tchkonia, 2013, Mechanisms and metabolic implications of regional differences among fat depots, Cell Metab, 17, 644, 10.1016/j.cmet.2013.03.008

Palmer, 2015, The sexual dimorphism of obesity, Mol Cell Endocrinol, 402, 113, 10.1016/j.mce.2014.11.029

Eslam, 2018, Genetics and epigenetics of NAFLD and NASH: clinical impact, J Hepatol, 68, 268, 10.1016/j.jhep.2017.09.003

Anstee, 2016, Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease, Gastroenterology, 150, 1728, 10.1053/j.gastro.2016.01.037

Abul-Husn, 2018, A protein-truncating HSD17B13 variant and protection from chronic liver disease, N Engl J Med, 378, 1096, 10.1056/NEJMoa1712191

Hernaez, 2011, Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis, Hepatology, 54, 1082, 10.1002/hep.24452

Szczepaniak, 2005, Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population, Am J Physiol Endocrinol Metab, 288, E462, 10.1152/ajpendo.00064.2004

Bril, 2015, Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients, Liver Int, 35, 2139, 10.1111/liv.12840

Bedogni, 2006, The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population, BMC Gatroenterol, 6, 33, 10.1186/1471-230X-6-33

Kantartzis, 2017, An extended fatty liver index to predict non-alcoholic fatty liver disease, Diabetes Metab, 43, 229, 10.1016/j.diabet.2016.11.006

Lee, 2010, Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations, J Hepatol, 52, 579, 10.1016/j.jhep.2010.01.008

Karlas, 2017, Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis, J Hepatol, 66, 1022, 10.1016/j.jhep.2016.12.022

Park, 2017, Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease, Gastroenterology, 152, 598, 10.1053/j.gastro.2016.10.026

Younossi, 2017, Diagnostic modalities for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and associated fibrosis, Hepatology

Verma, 2013, Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD), Liver Int, 33, 1398, 10.1111/liv.12226

Tapper, 2017, Use of liver imaging and biopsy in clinical practice, N Engl J Med, 377, 756, 10.1056/NEJMra1610570

Castera, 2015, Noninvasive assessment of liver fibrosis, Dig Dis, 33, 498, 10.1159/000374097

Cusi, 2014, Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease, J Hepatol, 60, 167, 10.1016/j.jhep.2013.07.042

Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496

Shah, 2009, Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 7, 1104, 10.1016/j.cgh.2009.05.033

2016, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease, Diabetologia, 59, 1121, 10.1007/s00125-016-3902-y

Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367

Rosenberg, 2004, Serum markers detect the presence of liver fibrosis: a cohort study, Gastroenterology, 127, 1704, 10.1053/j.gastro.2004.08.052

Ratziu, 2006, Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease, BMC Gastroenterol, 6, 6, 10.1186/1471-230X-6-6

Afdhal, 2015, Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study, Clin Gastroenterol Hepatol, 13, 772, 10.1016/j.cgh.2014.12.014

Loomba, 2018, Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions, J Hepatol, 68, 296, 10.1016/j.jhep.2017.11.028

Banerjee, 2014, Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease, J Hepatol, 60, 69, 10.1016/j.jhep.2013.09.002

Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 643, 10.1016/j.cgh.2014.04.014

McPherson, 2015, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management, J Hepatol, 62, 1148, 10.1016/j.jhep.2014.11.034

Bril, 2016, Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus, Endocrinol Metab Clin North Am, 45, 765, 10.1016/j.ecl.2016.06.005

Samuel, 2018, Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases, Cell Metab, 27, 22, 10.1016/j.cmet.2017.08.002

Santhekadur, 2018, Preclinical models of non-alcoholic fatty liver disease, J Hepatol, 68, 230, 10.1016/j.jhep.2017.10.031

Adams, 2017, Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases, Gut, 66, 1138, 10.1136/gutjnl-2017-313884

Pisto, 2014, Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study, BMJ Open, 4, e004973, 10.1136/bmjopen-2014-004973

Saltiel, 2001, Insulin signalling and the regulation of glucose and lipid metabolism, Nature, 414, 799, 10.1038/414799a

Stefan, 2013, The role of hepatokines in metabolism, Nat Rev Endocrinol, 9, 144, 10.1038/nrendo.2012.258

Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002/hep.29085

Hagström, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027

Tilg, 2017, NAFLD and diabetes mellitus, Nat Rev Gastroenterol Hepatol, 14, 32, 10.1038/nrgastro.2016.147

Stefan, 2008, Identification and characterization of metabolically benign obesity in humans, Arch Intern Med, 168, 1609, 10.1001/archinte.168.15.1609

Kantartzis, 2010, The impact of liver fat vs visceral fat in determining categories of prediabetes, Diabetologia, 53, 882, 10.1007/s00125-010-1663-6

Fabbrini, 2009, Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity, Proc Natl Acad Sci USA, 106, 15430, 10.1073/pnas.0904944106

Fabbrini, 2015, Metabolically normal obese people are protected from adverse effects following weight gain, J Clin Invest, 125, 787, 10.1172/JCI78425

Lauridsen, 2018, Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: mendelian randomization and meta-analysis of 279 013 individuals, Eur Heart J, 39, 385, 10.1093/eurheartj/ehx662

Liu, 2017, Exome-wide association study of plasma lipids in >300,000 individuals, Nat Genet, 49, 1758, 10.1038/ng.3977

BasuRay, 2017, The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation, Hepatology, 66, 1111, 10.1002/hep.29273

Kollerits, 2009, Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins, Hum Mol Genet, 18, 4669, 10.1093/hmg/ddp424

Fan, 2016, Hepatic transmembrane 6 superfamily member 2 regulates cholesterol metabolism in mice, Gastroenterology, 150, 1208, 10.1053/j.gastro.2016.01.005

Musso, 2017, TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD, J Lipid Res, 58, 1221, 10.1194/jlr.M075028

Jo, 2013, Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor, Hepatology, 57, 1366, 10.1002/hep.26126

Männistö, 2014, Lipoprotein subclass metabolism in nonalcoholic steatohepatitis, J Lipid Res, 55, 2676, 10.1194/jlr.P054387

Lotta, 2016, Association between low-density lipoprotein cholesterol lowering genetic variants and risk of type 2 diabetes: a meta-analysis, JAMA, 316, 1383, 10.1001/jama.2016.14568

Stender, 2017, Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci, Nat Genet, 49, 842, 10.1038/ng.3855

Neuschwander-Tetri, 2015, Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial, Lancet, 385, 956, 10.1016/S0140-6736(14)61933-4

Ratziu, 2016, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, 150, 1147, 10.1053/j.gastro.2016.01.038

Friedman, 2018, A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis, Hepatology, 67, 1754, 10.1002/hep.29477

Ratziu, 2018, A critical review of endpoints for non-cirrhotic NASH therapeutic trials, J Hepatol, 68, 353, 10.1016/j.jhep.2017.12.001

Cusi, 2016, Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions, Diabetologia, 59, 1112, 10.1007/s00125-016-3952-1

Younossi, 2017, Current and future therapeutic regimens for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), Hepatology

Townsend, 2017, Review article: new treatments in non-alcoholic fatty liver disease, Aliment Pharmacol Ther, 46, 494, 10.1111/apt.14210

Diehl, 2017, Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis, N Engl J Med, 377, 2063, 10.1056/NEJMra1503519

Cusi, 2012, Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications, Gastroenterology, 142, 711, 10.1053/j.gastro.2012.02.003

Rowe, 2018, Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease, Lancet Gastroenterol Hepatol, 3, 66, 10.1016/S2468-1253(17)30142-5

Marchesini, 2016, Diet, weight loss, and liver health in nonalcoholic fatty liver disease: pathophysiology, evidence, and practice, Hepatology, 63, 2032, 10.1002/hep.28392

Barb, 2016, Pharmacological management of nonalcoholic fatty liver disease, Metabolism, 65, 1183, 10.1016/j.metabol.2016.04.004

Promrat, 2010, Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis, Hepatology, 51, 121, 10.1002/hep.23276

Vilar-Gomez, 2015, Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis, Gastroenterology, 149, 367, 10.1053/j.gastro.2015.04.005

Goossens, 2016, Nonalcoholic steatohepatitis is associated with increased mortality in obese patients undergoing bariatric surgery, Clin Gastroenterol Hepatol, 14, 1619, 10.1016/j.cgh.2015.10.010

Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326

Cusi, 2016, Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial, Ann Intern Med, 165, 305, 10.7326/M15-1774

Aithal, 2008, Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis, Gastroenterology, 135, 1176, 10.1053/j.gastro.2008.06.047

Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929

Bril, 2018, Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes, Clin Gastroenterol Hepatol, 16, 558, 10.1016/j.cgh.2017.12.001

Musso, 2017, Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis, JAMA Intern Med, 177, 633, 10.1001/jamainternmed.2016.9607

DeFronzo, 2011, Pioglitazone for diabetes prevention in impaired glucose tolerance, N Engl J Med, 364, 1104, 10.1056/NEJMoa1010949

Kernan, 2016, Pioglitazone after ischemic stroke or transient ischemic attack, N Engl J Med, 374, 1321, 10.1056/NEJMoa1506930

Yau, 2013, The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus, Curr Diab Rep, 13, 329, 10.1007/s11892-013-0378-8

Bril, 2016, Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD, J Clin Endocrinol Metab, 101, 644, 10.1210/jc.2015-3111

Lincoff, 2007, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials, JAMA, 298, 1180, 10.1001/jama.298.10.1180

Mazzone, 2006, Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial, JAMA, 296, 2572, 10.1001/jama.296.21.joc60158

Nissen, 2008, Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial, JAMA, 299, 1561, 10.1001/jama.299.13.1561

Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9

Zghebi, 2016, Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records, Diabetes Obes Metab, 18, 916, 10.1111/dom.12692

Strongman, 2018, Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study, BMJ Open Diabetes Res Care, 6, e000481, 10.1136/bmjdrc-2017-000481

Vaccaro, 2017, Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial, Lancet Diabetes Endocrinol, 5, 887, 10.1016/S2213-8587(17)30317-0

Balas, 2007, Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis, J Hepatol, 47, 565, 10.1016/j.jhep.2007.04.013

Viscoli, 2017, Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial, J Clin Endocrinol Metab, 102, 914

Clarke, 2017, Pioglitazone improves left ventricular diastolic function in subjects with diabetes, Diabetes Care, 40, 1530, 10.2337/dc17-0078

Lewis, 2015, Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes, JAMA, 314, 265, 10.1001/jama.2015.7996

Davidson, 2018, An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis, Diabetes Res Clin Pract, 135, 102, 10.1016/j.diabres.2017.11.002

Armstrong, 2016, Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo controlled phase 2 study, Lancet, 387, 679, 10.1016/S0140-6736(15)00803-X

Dhir, 2018, Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option, J Investig Med, 66, 7, 10.1136/jim-2017-000554

Cefalu, 2018, Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care editors' expert forum, Diabetes Care, 41, 14, 10.2337/dci17-0057

DeFronzo, 2017, Renal, metabolic and cardiovascular considerations of SGLT2 inhibition, Nat Rev Nephrol, 13, 11, 10.1038/nrneph.2016.170